Analysis Published In New England Journal of Medicine Highlights Discovery Of New Predictive Biomarkers For Vectibix®

Analysis Published In New England Journal of Medicine Highlights Discovery Of
            New Predictive Biomarkers For Vectibix® (Panitumumab)

Study Links RAS Mutations to Vectibix Clinical Response in Patients With
Metastatic Colorectal Cancer

PR Newswire

THOUSAND OAKS, Calif., Sept. 11, 2013

THOUSAND OAKS, Calif., Sept. 11, 2013 /PRNewswire/ --Amgen (NASDAQ:AMGN)
today announced the publication of a biomarker analysis of Vectibix^®
(panitumumab) in combination with FOLFOX, a type of oxaliplatin-based
chemotherapy, for the first-line treatment of patients with metastatic
colorectal cancer (mCRC). Published in the New England Journal of Medicine,
the analysis found that RAS mutations, beyond the known KRAS exon 2 mutations,
predict lack of response to Vectibix in combination with FOLFOX. RASmutations
are mutations occurring in exons 2, 3 and 4 ofKRASandNRAS.

"While the KRAS exon 2 biomarker is well-known and has facilitated selection
of patients more likely to respond to anti-EGFR treatment, we found that there
were still some patients who didn't benefit from treatment," said Jean-Yves
Douillard, M.D., Ph.D., professor of medical oncology, Centre R Gauducheau,
France and PRIME trial lead investigator and study author. "This analysis is
important as it furthers our understanding of tumor genetics and allows
physicians to more accurately match patients to effective treatments."

This predefined retrospective subset analysis of the PRIME ('203) study
assessed the safety and efficacy of Vectibix plus FOLFOX, compared to FOLFOX
alone based on RAS or BRAF mutation status. By more precisely narrowing the
pool of patients treated with Vectibix plus FOLFOX to those with wild-type
RAS, greater improvements in overall survival (OS) and progression-free
survival (PFS) were observed. Specifically, previous data found that OS was
improved by 4.4 months in patients with wild-type KRAS. By further narrowing
to patients with wild-type RAS, an improvement in OS of 5.8 months was
observed.

In patients with wild-type RAS, OS was 26.0 months and 20.2 months (HR = 0.78;
95 percent CI, 0.62-0.99) and PFS was 10.1 months and 7.9 months (HR = 0.72,
95 percent CI, 0.58-0.90) in the Vectibix plus FOLFOX arm compared to the
FOLFOX alone arm, respectively. BRAF mutations were not observed to have
predictive value.

Conversely, in the patients with RAS mutations, inferior OS (HR = 1.25, 95
percent CI, 1.02-1.55) and PFS (HR = 1.34, 95 percent CI, 1.07-1.60) were
observed in the Vectibix plus FOLFOX arm compared to the FOLFOX alone arm.
Amgen has informed investigators and physicians of this important new safety
information, and is working with regulatory agencies regarding appropriate
communication of the outcomes of the analysis.

"Amgen is proud of our continuing work to identify and establish predictive
biomarkers, like RAS, that will help better inform therapeutic decisions,"
said Sean E. Harper, M.D., executive vice president of Research and
Development at Amgen. "As a result of this information, the European
Commission has refined the prescribing information for Vectibix to the
treatment of adult patients with wild-type RAS metastatic colorectal cancer."

No new safety signals were identified in this analysis.

PRIME ('203) Study Design
The PRIME (Panitumumab Randomized trial In combination with chemotherapy for
Metastatic colorectal cancer to determine Efficacy) ('203) trial is a global,
multicenter, randomized Phase 3 study designed to evaluate Vectibix (6.0 mg/kg
every two weeks) plus FOLFOX versus FOLFOX alone in patients with wild-type
KRAS exon 2 mCRC. The primary endpoint is PFS.

The primary objective of this predefined retrospective subset analysis was to
determine the effect of Vectibix plus FOLFOX versus FOLFOX alone on OS and PFS
in patients with mCRC based on RAS or BRAF mutation status. The analysis
included 512 patients who were identified with wild-type RAS tumors.

About KRAS and RAS
Results from studies performed over the last 30 years indicate that KRAS plays
an important role in cell growth regulation. In mCRC, EGFR transmits signals
through a set of intracellular proteins. Upon reaching the nucleus, these
signals instruct the cancer cell to reproduce and metastasize, leading to
cancer progression.^1 Anti-EGFR antibody therapies work by inhibiting the
activation of EGFR, thereby inhibiting downstream events that lead to
malignant signaling. However, in patients whose tumors harbor a mutated KRAS
gene, the KRAS protein is always turned "on," regardless of whether the EGFR
has been activated or therapeutically inhibited. Common KRAS mutations
occurring in exon 2 (codons 12/13) are present in approximately 40 to 50
percent of mCRC patients.^2,3 Additional RAS mutations occurred in
approximately 17 percent of patients with wild-type KRAS exon 2 tumors.

About Colorectal Cancer
Colorectal cancer is the third most common cancer found in both men and women
in the U.S., and is the second leading cause of cancer deaths.^4,5
Approximately 1.2 million cases of colorectal cancer are expected to occur
globally. The highest incidence rates are found in Japan, North America, parts
of Europe, New Zealand and Australia, and rates are low in Africa and
Southeast Asia.^6

About Vectibix
Vectibix is the first fully human anti-EGFR antibody approved by the U.S. Food
and Drug Administration (FDA) for the treatment of mCRC. Vectibix was approved
in theU.S. in September 2006 as a single agent for the treatment of patients
with EGFR-expressing mCRC with disease progression on or following
fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy
regimens. The effectiveness of Vectibix as a single agent for the treatment of
EGFR-expressing mCRC is based on PFS. More than half of patients who receive
Vectibix monotherapy respond to treatment with an average six month PFS
benefit. Currently, no data are available that demonstrate an improvement in
disease-related symptoms or increased survival with Vectibix.

Retrospective subset analyses of mCRC trials have not shown a treatment
benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12
or 13. Use of Vectibix is not recommended for the treatment of mCRC with these
mutations.^7

Important U.S. Product Information
Vectibix is indicated as a single agent for the treatment of EGFR-expressing
mCRC with disease progression on or following fluoropyrimidine-, oxaliplatin-
and irinotecan-containing chemotherapy regimens. The effectiveness of Vectibix
as a single agent for the treatment of EGFR-expressing mCRC is based on
progression-free survival. Currently, no data demonstrate an improvement in
disease-related symptoms or increased survival with Vectibix.

Vectibix is not indicated for the treatment of patients with KRAS
mutation-positive mCRC or for whom KRAS mCRC status is unknown. Retrospective
subset analyses of metastatic colorectal cancer trials have not shown a
treatment benefit for Vectibix in patients whose tumors had KRAS mutations in
codon 12 or 13. Vectibix in combination with oxaliplatin-based chemotherapy is
not indicated for the treatment of patients with RAS (KRAS or NRAS)
mutation-positive mCRC or for whom RAS status is unknown.

WARNING: DERMATOLOGIC TOXICITY and INFUSION REACTIONS
Dermatologic Toxicity: Dermatologic toxicities occurred in 89 percent of
patients and were severe (NCI-CTC grade 3 or higher) in 12 percent of patients
receiving Vectibix monotherapy. [See Dosage and Administration (2.1), Warnings
and Precautions (5.1), and Adverse Reactions (6.1)].

Infusion Reactions: Severe infusion reactions occurred in approximately one
percent of patients. Fatal infusion reactions occurred in postmarketing
experience [See Dosage and Administration (2.1), Warnings and Precautions
(5.2), and Adverse Reactions (6.1, 6.3)].

The most common adverse events of Vectibix are skin rash with variable
presentations, hypomagnesemia, paronychia, fatigue, abdominal pain, nausea and
diarrhea, including diarrhea resulting in dehydration.

The most serious adverse reactions of Vectibix are pulmonary fibrosis,
pulmonary embolism, severe dermatologic toxicity complicated by infectious
sequelae and septic death, infusion reactions, abdominal pain, hypomagnesemia,
nausea, vomiting and constipation.

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC) reports filed
by Amgen, including Amgen's most recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K.Please refer to Amgen's
most recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to our business. Unless otherwise
noted, Amgen is providing this information as of Sept. 11, 2013, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar variability in
the future. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates that are
derived from relationships may be subject to disputes between the parties or
may prove to be not as effective or as safe as we may have believed at the
time of entering into such relationship. Also, we or others could identify
safety, side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government investigations,
litigation and product liability claims. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the U.S.
government, we could become subject to significant sanctions. We depend on
third parties for a significant portion of our manufacturing capacity for the
supply of certain of our current and future products and limits on supply may
constrain sales of certain of our current products and product candidate
development.

In addition, sales of our products are affected by the reimbursement policies
imposed by third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. We cannot guarantee that we will be able to
produce commercially successful products or maintain the commercial success of
our existing products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant problems
with a product similar to one of our products that implicate an entire class
of products could have a material adverse effect on sales of the affected
products and on our business and results of operations.

The scientific information discussed in this news release relating to new
indications for our products is preliminary and investigative and is not part
of the labeling approved by the U.S. Food and Drug Administration (FDA) for
the products. The products are not approved for theinvestigational use(s)
discussed in this news release, and no conclusions can or should be drawn
regarding the safety or effectiveness of the products for theseuses. Only the
FDA can determine whether the products are safe and effective for these uses.
Healthcareprofessionals shouldrefer to and rely upon the FDA-approved
labeling for the products, and not the information discussed in this news
release.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

^1 Malumbres, M. and Barbacid, M. RAS oncogenes: the first 30 years. Nature
Reviews Cancer.  3:459-65, 2003.
^2 Karapentis C, S. Snell, L, E. The Laboratory Assessment of KRAS Mutation
Status in  Colorectal Cancer. Asia Pacific Journal of Oncology and
Hematology. 2010.
^3 Friday BB and Adjei AA. K-ras as a target for cancer therapy. Biochim.
Biophys. Acta 1756:  127-144, 2005.
^4 Cancer Facts and Figures 2013. American Cancer Society website. 
http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
Accessed March 25, 2013.
^5 Colorectal Cancer Prevention (PDQ^®). National Cancer Institute. Accessed
March 25, 2013. 
http://www.cancer.gov/cancertopics/pdq/prevention/colorectal/HealthProfessional/page3.
^6 Jemal. Global Cancer Statistics. CA Cancer J Clin. 2011;61:69-90.
^7 Vectibix (panitumumab) Prescribing Information. Thousand Oaks, Calif:
Amgen; 2011.

SOURCE Amgen

Website: http://www.amgen.com